BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24012486)

  • 1. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging.
    Seynhaeve ALB; Dicheva BM; Hoving S; Koning GA; Ten Hagen TLM
    J Control Release; 2013 Nov; 172(1):330-340. PubMed ID: 24012486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
    Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
    J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.
    Ito K; Hamamichi S; Asano M; Hori Y; Matsui J; Iwata M; Funahashi Y; Umeda IO; Fujii H
    Cancer Sci; 2016 Jan; 107(1):60-7. PubMed ID: 26509883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular PK/PD Relationships of Free and Liposomal Doxorubicin: Quantitative Analyses and PK/PD Modeling.
    Soininen SK; Vellonen KS; Heikkinen AT; Auriola S; Ranta VP; Urtti A; Ruponen M
    Mol Pharm; 2016 Apr; 13(4):1358-65. PubMed ID: 26950248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors.
    Laginha KM; Verwoert S; Charrois GJ; Allen TM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6944-9. PubMed ID: 16203786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular trafficking of a pH-responsive drug metal complex.
    Kheirolomoom A; Ingham ES; Commisso J; Abushaban N; Ferrara KW
    J Control Release; 2016 Dec; 243():232-242. PubMed ID: 27746275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equivalency challenge: Evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model.
    Smith JA; Mathew L; Burney M; Nyshadham P; Coleman RL
    Gynecol Oncol; 2016 May; 141(2):357-363. PubMed ID: 26946092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple way to enhance Doxil® therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer.
    Zhao Y; Alakhova DY; Kim JO; Bronich TK; Kabanov AV
    J Control Release; 2013 May; 168(1):61-9. PubMed ID: 23474033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin.
    Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Kikuchi H; Ishihara H
    Int J Pharm; 2014 Dec; 476(1-2):205-12. PubMed ID: 25280884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
    Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
    Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations.
    Luo R; Li Y; He M; Zhang H; Yuan H; Johnson M; Palmisano M; Zhou S; Sun D
    Int J Pharm; 2017 Mar; 519(1-2):1-10. PubMed ID: 28063903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel two-step mild hyperthermia for advanced liposomal chemotherapy.
    Li L; ten Hagen TL; Haeri A; Soullié T; Scholten C; Seynhaeve AL; Eggermont AM; Koning GA
    J Control Release; 2014 Jan; 174():202-8. PubMed ID: 24269966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A quantitative study of the intracellular fate of pH-responsive doxorubicin-polypeptide nanoparticles.
    Wang J; Bhattacharyya J; Mastria E; Chilkoti A
    J Control Release; 2017 Aug; 260():100-110. PubMed ID: 28576641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance guided high-intensity focused ultrasound mediated hyperthermia improves the intratumoral distribution of temperature-sensitive liposomal doxorubicin.
    de Smet M; Hijnen NM; Langereis S; Elevelt A; Heijman E; Dubois L; Lambin P; Grüll H
    Invest Radiol; 2013 Jun; 48(6):395-405. PubMed ID: 23399809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manganese-52: applications in cell radiolabelling and liposomal nanomedicine PET imaging using oxine (8-hydroxyquinoline) as an ionophore.
    Gawne P; Man F; Fonslet J; Radia R; Bordoloi J; Cleveland M; Jimenez-Royo P; Gabizon A; Blower PJ; Long N; de Rosales RTM
    Dalton Trans; 2018 Jul; 47(28):9283-9293. PubMed ID: 29796500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response.
    Lu T; Lokerse WJM; Seynhaeve ALB; Koning GA; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):425-437. PubMed ID: 26541464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil).
    Tsukioka Y; Matsumura Y; Hamaguchi T; Koike H; Moriyasu F; Kakizoe T
    Jpn J Cancer Res; 2002 Oct; 93(10):1145-53. PubMed ID: 12417045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.